Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT03373877 trial: what clinicians have said so far
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
- NCT03373877 ↗
- Terminated
- Samus Therapeutics, Inc.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT03373877 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03373877 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
- Interventions
- PU-H71; Ruxolitinib
- Arms
- Dose 1: PU-H71 225 mg/m2 + ruxolitinib · Experimental
- Dose 2: PU-H71 300 mg/m2 + ruxolitinib · Experimental
- Dose 3: PU-H71 400 mg/m2 + ruxolitinib · Experimental
- Dose 4: PU-H71 600 mg/m2 + ruxolitinib · Experimental
- Enrollment
- 4
- Primary outcomes
- Incidence of adverse events
- Maximum Tolerated Dose of PU-H71 (MTD)
- Recommended Phase 2 Dose of PU-H71 (RP2D)
- Pharmacokinetic profile of PU-H71: Area under the plasma concentration versus time curve (AUC)
- Pharmacokinetic profile of PU-H71: Trough plasma concentration (Cmin)
- Pharmacokinetic profile of PU-H71: Peak plasma concentration (Cmax)
- Pharmacokinetic profile of PU-H71: Time to maximum plasma concentration (Tmax)
- Pharmacokinetic profile of PU-H71: Plasma half-life (T1/2)
- Sponsor
- Samus Therapeutics, Inc.
- Start
- May 24, 2018
- Primary completion
- Oct 17, 2019
- Results posted
- No
- Registry record
- NCT03373877 · updated Nov 15, 2022